Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023)
Denali Therapeutics (DNLI) reported EBIT Margin of 8981.45% for Q3 2023, up 4943485.0% year-over-year from N/an in Q3 2022, and down 15595.1% quarter-over-quarter from 57.96% in Q2 2023.
Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 6 years of EBIT Margin data on file, last reported at 8981.45% in Q3 2023.
- EBIT Margin for Q3 2023 came in at 8981.45%, up 4943485.0% year-over-year; the trailing twelve-month figure through Jun 2024 was 37938.04% (down 3788998.0% YoY), and the FY2023 annual result was 59.51%, up 996827.0% from the prior year.
- EBIT Margin slipped to 8981.45% in Q3 2023 per DNLI's latest filing, from 57.96% in the prior quarter.
- Over five years, EBIT Margin peaked at 77.04% in Q4 2020 and troughed at 7122000.0% in Q1 2021.
- A 5-year average of 454218.99% and a median of 1053.44% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2021 and 2022: EBIT Margin plunged 700667885 bps in 2021, then surged 712184220 bps in 2022.
- A 5-year view of EBIT Margin shows it stood at 1236.26% in 2019, then jumped by 106 bps to 77.04% in 2020, then sank by 900 bps to 616.28% in 2021, then slumped by 71 bps to 1053.44% in 2022, then slumped by 753 bps to 8981.45% in 2023.
- Business Quant data shows DNLI's EBIT Margin at 8981.45% in Q3 2023, 57.96% in Q2 2023, and 343.8% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -8,981.45% |
| Jun 30, 2023 | 57.96% |
| Mar 31, 2023 | -343.80% |
| Dec 31, 2022 | -1,053.44% |
| Sep 30, 2022 | -58,416.30% |
| Jun 30, 2022 | -117.03% |
| Mar 31, 2022 | -157.80% |
| Dec 31, 2021 | -616.28% |
| Sep 30, 2021 | -1,619.55% |
| Jun 30, 2021 | -412.11% |
| Mar 31, 2021 | -7,122,000.00% |
| Dec 31, 2020 | 77.04% |
| Sep 30, 2020 | -1,202,320.00% |
| Jun 30, 2020 | -1,048.01% |
| Mar 31, 2020 | -115,321.15% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -52,244.79% |
| Jun 30, 2019 | -63,396.97% |
| Mar 31, 2019 | -1,010.89% |
| Dec 31, 2018 | 59.48% |